AKCI

AKCI is a type of AURKC-IκBα interaction inhibitor, with an IC50 value of 24.9 μM. In MDA-MB-231 cells, AKCI can induce G2/M cell cycle arrest by regulating the p53/p21/CDC2/cyclin B1 pathway, inhibit cell migration and invasion, and reduce colony formation and tumor growth. AKCI can be used for research on breast cancer[1].

Product Specifications

CAS Number

669750-88-3

UNSPSC

12352005

Target

Cyclin G-associated Kinase (GAK) ; MDM-2/p53

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/akci.html

Smiles

CC1=CC=CC2=C(N=C(N=C12)NC3=NCN(CCN4CCOCC4)CN3)C

Molecular Formula

C19H27N7O

Molecular Weight

369.46

References & Citations

[1]Han EH, et al. A small-molecule inhibitor targeting the AURKC-IκBα interaction decreases transformed growth of MDA-MB-231 breast cancer cells. Oncotarget. 2017 Jun 29;8 (41) :69691-69708.